MRUS Company Profile and Key Details

Q: Who are the executives of MRUS?

Mr. Gregory D. PerryChief Financial Officer & Vice ChairmanDr. Sven Ante Lundberg M.D.Chief Executive Officer, Pres & Executive DirectorMr. Peter B. Silverman J.D.EVice President, Company Sec., Chief Operating Officer, Gen. Counsel, Chief Intellectual Property Officer & Head of US LegalDr. Cecilia Anna Wilhelmina Geuijen Ph.D.Chief Scientific Officer & Senior Vice PresidentMr. Hui Liu Ph.D.Chief Bus. Officer, Executive Vice President & Head of Merus U.S.Harry ShumanChief Accounting OfficerDr. Hennie HoogenboomCo-Founder and Scientific AdvisorMr. Alexander Berthold Hendrik Bakker Ph.D.Chief Devel. Officer & Executive Vice PresidentMr. Cornelis Adriaan de Kruif Ph.D.Chief Technology Officer & Executive Vice PresidentMs. Jillian ConnellVice President of Investor Relations & Corporation CommunicationsDr. Andrew Joe M.D.Chief Medical Officer & Senior Vice PresidentDr. Hui Liu Ph.D.Chief Bus. Officer, Executive Vice President & Head of Merus U.S.

NASDAQ : MRUS

Merus NV

$90.00

At Close 4:00 PM

Not Actively Trading

60.76

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Merus N.V. (MRUS) stock remained unchanged at $90.00 a share on NASDAQ. The stock opened at $90.00, fluctuating between $90.00 to $90.00 during the session.

Stock Snapshot

Prev. Close

6.83B

Market Cap

Day Low

-17.045454545454547

P/E Ratio

-5.28

EPS (TTM)

-2.5

Cash Flow per Share

Open

75.84M

Number of Shares

Day High

86.74%

Free Float in %

6.16

Book Value

2.72M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 29, 2025	96.86	96.86	87.14	90.00	2.72M
Dec 26, 2025	96.88	97.00	96.84	96.92	362.8K
Dec 24, 2025	96.92	96.96	96.91	96.91	193.83K
Dec 23, 2025	96.95	96.98	96.90	96.90	377.26K
Dec 22, 2025	96.90	97.02	96.90	96.95	500.18K
Dec 19, 2025	96.93	97.14	96.82	97.01	915.31K
Dec 17, 2025	96.95	96.99	96.85	96.89	1.5M
Dec 16, 2025	96.77	96.98	96.73	96.92	1.3M
Dec 15, 2025	96.87	96.93	96.69	96.82	912.61K
Dec 12, 2025	96.80	96.94	96.80	96.93	708.55K
Dec 11, 2025	96.77	96.79	96.60	96.63	1.1M
Dec 10, 2025	96.65	96.83	96.65	96.77	3.13M
Dec 09, 2025	96.25	96.42	96.25	96.36	1.36M
Dec 08, 2025	96.20	96.34	96.11	96.27	589.73K
Dec 05, 2025	96.20	96.25	96.09	96.14	703.88K
Dec 04, 2025	96.11	96.27	96.01	96.22	1.42M
Dec 03, 2025	96.06	96.16	96.01	96.12	1.55M
Dec 02, 2025	96.00	96.08	95.83	95.99	1.49M
Dec 01, 2025	96.14	96.17	95.88	95.94	1.51M
Nov 28, 2025	96.10	96.19	96.01	96.14	396.38K

Contact Details

Utrecht, 3584 CM

Netherlands

https://www.merus.nl 313 025 38800

About Company

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Stock Peers

ARGX

-1.01-0.12%

argenx SE$833.54 REGN

4.68+0.60%

Regeneron Pharmaceuticals, Inc.$783.65 UTHR

0.28+0.06%

United Therapeutics Corporation$476.13 MDGL

-7.21-1.50%

Madrigal Pharmaceuticals, Inc.$473.79 VRTX

3.78+0.82%

Vertex Pharmaceuticals Incorporated$465.02 PRAX

9.63+2.98%

Praxis Precision Medicines, Inc.$332.92 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-13.8-4.28%

Alnylam Pharmaceuticals, Inc.$308.48 KRYS

-2.39-0.88%

Krystal Biotech, Inc.$270.26 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

The stock is currently mid-range between its 52-week high and low $33.19 and $97.14. With a market capitalization of about $6.83 billion, Merus N.V. is classified as a mid-cap and shows market-like volatility (beta ~1.06). Key stats such as the average daily volume over the past year has been around 1.72 million shares, trading with heavier-than-usual volume. Headquartered in Utrecht, None, Merus N.V. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jan van de Winkel, the company employs approximately 260 people and listed since May 19, 2016. Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -6.52%, SMA50 -5.96%, SMA200 32.76%). The stock’s 14-day RSI is 14.67 (weak momentum), while the ATR of 0.95 points to moderate volatility. The stock remains hovering near 52-week lows, trading -7.35% below its high and over 171.17% above its low.

Valuation Metrics

Merus N.V. trades at a P/E ratio of -20.34, slightly below the S&P 500 average, with a price-to-sales ratio of 133.38 and a price-to-book ratio of 10.29 reflecting a rich premium to book value. The P/FCF stands at -21.47, also below market averages. Compared to sector medians, Merus N.V. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Merus N.V. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$10.21. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Merus N.V. generated EPS of -$5.33 over the past year. Five-year average earnings growth is -8.04%. Wall Street analysts project EPS growth of -8.15% annually over the next five years. The latest quarter delivered EPS of -$1.23. The next quarter is forecast at -$1.24. Next year's EPS is expected at -$14.77. Analyst sentiment is neutral. Analyst rating data shows there are 2 Strong Buy ratings, 8 Buy ratings, 12 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $112.00 to $70.00. The high target offers 24.44% upside. The low target suggests -22.22% downside. The mean target is $94.73. This offers 5.26% upside. Merus N.V. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 31, 2025, missed forecasts by 0.0%. The prior quarter beat by 20.19%. Over the last six quarters, Apple has recorded several small beats. These include 5.56% in October 31, 2024.

Shareholding & Insider Activity

Merus N.V. has 75.63 million shares outstanding. The public float is 65.61 million shares, elevated short interest at 5.90% of float. This equals 4.44 million shares. The short ratio is 6.49 days. Institutional investors hold 106.23% of the float. Insiders own 2.29%. BVF PARTNERS L P/IL holds 232.75 thousand shares, Throsby Mark has 45.52 thousand shares and Lundberg Sven Ante has 40.58 thousand shares. Over the past six months, insider transactions show net buying. They sold 10.00 thousand shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Merus NV generated $43.95M in revenue, or $0.85 per share. Gross margin was -189.91%, operating margin -356.22%, and net profit margin -352.56%. Returns are negative, with ROA at -33.79% and ROE at -43.48%.
On valuation metrics, Merus NV trades at a P/E of -20.34, P/S of 133.38 and P/B of 10.29. The current ratio is 7.97 and quick ratio is 7.97. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 122.36 days. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -30.17.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Merus NV posted revenue of $43.95M, down slightly from $41.59M in the prior quarter. Gross profit was - $83.46M (margin -189.91%). Operating income was - $156.55M (margin -356.2%). Net income was- $154.94M (EPS - $3.00).
The company ended the quarter with $355.18M in cash and short-term investments, a total debt of $12.16M, and net debt of - $192.88M. Total assets were $458.49M, with equity of $356.34M. Financials further reflected weakness, with operating cash flow of - $142.21M, free cash flow of - $146.19M, and capital expenditures of - $3.98M.

Price Forecast & Outlook

Our AI price prediction model suggests that Merus N.V. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.84%, with price expected at $93.46 by January 12, 2026, within a range of $92.47 to $94.49 3-Month Outlook: Projected rise of 38.48%, reaching $124.63 by March 27, 2026, with a range of $123.70 to $125.83. 1-Year Outlook: Projected gain of 30.34%, with price at $117.31 by December 29, 2026, within a range of $113.99 to $121.16.

Key Takeaways

currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Merus N.V. trading at a premium to the broader market with a P/E of -20.34. Analyst sentiment is cautious, with the majority of ratings in Market Perform territory and a mean price target of $66.58, suggesting -26.02% downside. Our AI forecast model points to short-term strength (3.84% over two weeks), a medium-term rise (38.48% over three months), and a longer-term gain (30.34% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Merus N.V. (MRUS) stock price?

Merus N.V. (NASDAQ: MRUS) stock price is $90.00 in the last trading session. During the trading session, MRUS stock reached the peak price of $90.00 while $90.00 was the lowest point it dropped to. The percentage change in MRUS stock occurred in the recent session was 0% while the dollar amount for the price change in MRUS stock was $0.00.

MRUS's industry and sector of operation?

The NASDAQ listed MRUS is part of Biotechnology industry that operates in the broader Healthcare sector. Merus N.V. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MRUS?

Mr. Gregory D. Perry
Chief Financial Officer & Vice Chairman
Dr. Sven Ante Lundberg M.D.
Chief Executive Officer, Pres & Executive Director
Mr. Peter B. Silverman J.D.
EVice President, Company Sec., Chief Operating Officer, Gen. Counsel, Chief Intellectual Property Officer & Head of US Legal
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.
Chief Scientific Officer & Senior Vice President
Mr. Hui Liu Ph.D.
Chief Bus. Officer, Executive Vice President & Head of Merus U.S.
Harry Shuman
Chief Accounting Officer
Dr. Hennie Hoogenboom
Co-Founder and Scientific Advisor
Mr. Alexander Berthold Hendrik Bakker Ph.D.
Chief Devel. Officer & Executive Vice President
Mr. Cornelis Adriaan de Kruif Ph.D.
Chief Technology Officer & Executive Vice President
Ms. Jillian Connell
Vice President of Investor Relations & Corporation Communications
Dr. Andrew Joe M.D.
Chief Medical Officer & Senior Vice President
Dr. Hui Liu Ph.D.
Chief Bus. Officer, Executive Vice President & Head of Merus U.S.

How MRUS did perform over past 52-week?

MRUS's closing price is 171.17% higher than its 52-week low of $33.19 where as its distance from 52-week high of $97.14 is -7.35%.

How many employees does MRUS have?

Number of MRUS employees currently stands at 260.

Link for MRUS official website?

Official Website of MRUS is: https://www.merus.nl

How do I contact MRUS?

MRUS could be contacted at phone 313 025 38800 and can also be accessed through its website. MRUS operates from Yalelaan 62, Utrecht, 3584 CM, Netherlands.

How many shares of MRUS are traded daily?

MRUS stock volume for the day was 2.72M shares. The average number of MRUS shares traded daily for last 3 months was 1.72M.

What is the market cap of MRUS currently?

The market value of MRUS currently stands at $6.83B with its latest stock price at $90.00 and 75.84M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	260
Beta	1.06
Sales or Revenue	$43.95M
5Y Sales Change%	-0.472%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

MRUS Company Profile and Key Details

Merus NV

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Shareholding & Insider Activity

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Price Forecast & Outlook